Durvalumab/Chemo Maintenance Followed by Olaparib Confers PFS Advantage in Endometrial Cancer
Durvalumab plus first-line chemotherapy, followed by maintenance treatment with durvalumab plus olaparib, emerges as a potentially effective combination for patients with limited treatment options.
Neoadjuvant, Adjuvant Nivolumab Improve EFS in Resectable NSCLC
Treatment with neoadjuvant nivolumab, followed by adjuvant nivolumab after surgery, led to significantly improved event-free survival in the first phase 3 perioperative study in patients with resectable non-small cell lung cancer.
MPN-Associated Anemia: What Nurses Should Look Out For
Oncology nurses should have open communication with patients and closely monitor their hemoglobin levels when dealing with patients with myelofibrosis who have or may have anemia.
Know What Questions to Ask When Treating MPNs
Oncology nurses must know about disease symptoms and patient comorbidities when treating individuals with myeloproliferative neoplasms.
ASP-1929 Plus Pembrolizumab Generates Clinical Activity in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
ASP-1929, an antibody-dye conjugate, plus pembrolizumab, induced a 29.4% overall response rate in patients with recurrent or metastatic head and neck squamous cell carcinoma.
Spleen Volume Reduction Associated With Overall Survival Benefit in Patients With Myelofibrosis Receiving Pacritinib
For patients with myelofibrosis receiving pacritinib, spleen volume reduction was associated with improved overall survival.
Lower Trastuzumab Deruxtecan Dose Appears Optimal in HER2+ mCRC
Patients with HER2-positive, metastatic colorectal cancer derived clinical benefit from a 5.4 mg/kg dose of trastuzumab deruxtecan.
Abbey Kaler, MS, APRN, FNP-C, CMSRN, Wins CURE's 2023 Extraordinary Healer Award
Abbey Kaler, MS, APRN, FNP-C, CMSRN, demonstrated extraordinary oncology nursing by being a consistent champion of the patient’s voice.
Second-Line Axi-Cel Bests HDT/HSCT in Prolonging Overall Survival in R/R LBCL
Axicabtagene ciloleucel delivered superior overall survival compared with standard of care in patients with early relapsed or refractory large B-cell lymphoma.
Trastuzumab Deruxtecan Demonstrates Clinical Activity Across Numerous HER2+ Solid Tumors
In the phase 2 DESTINY-PanTumor02 trial, trastuzumab deruxtecan elicited clinical activity across a range of HER2 expressing solid tumors.
Luspatercept Elicits High Transfusion Independence Rates in Lower-Risk MDS
Over half of patients with lower-risk myelodysplastic syndrome treated with luspatercept achieved transfusion independence.
Perioperative Durvalumab Plus Neoadjuvant Chemotherapy Outperforms Placebo in Resectable NSCLC
The pathologic complete response rate with durvalumab was 17.2% vs 4.3% with placebo, reflecting an absolute difference of 12.9%.
Neoadjuvant Olaparib Leads to High Optimal Resection Rate in BRCA-Mutated Ovarian Cancer
With a follow-up of 11.7 months, the estimated 12-month progression-free survival rate was 81% in patients who received neoadjuvant olaparib for BRCA-positive ovarian cancer.
Ponatinib Plus Reduced-Intensity Chemotherapy Outperforms Imatinib in Newly Diagnosed Ph+ ALL
Frontline ponatinib plus reduced-intensity chemotherapy yielded a higher minimal residual disease-negative complete remission rate than imatinib in the phase 3 PhALLCON study.
Neoadjuvant Pembrolizumab Elicits High Response Among dMMR/MSI-H Solid Tumors
Neoadjuvant pembrolizumab elicited high clinical activity in patients with mismatch repair deficiency/microsatellite instability high solid tumors and was well tolerated.
Optimizing Frailty Tools Are A Vital Component of Improving Care Across Hematologic Malignancies
Nilesh Kalariya, PhD, AGPCNP-BC, AOCNP, discusses key data of interest from the 2022 American Society of Hematology Meeting.
APRN-Led Discharge Program Reduces Readmission Rates Following Treatment With Immune Checkpoint Inhibitors
APRNs developed a discharge program which reduced readmission rates for patients receiving immunotherapy for advanced melanoma.
Helping Patients Navigate Complementary Treatments
Holistic options like acupuncture and music therapy may benefit those undergoing cancer treatment.
Promising Selpercatinib Data Highlight Value of RET Fusion Testing for Patients With Solid Tumors
Selpercatinib demonstrated a promising efficacy profile in patients with RET-fusion positive solid tumors.
Promising Pathologic Complete Response Rate Observed With Neoadjuvant Cemiplimab in Cutaneous Squamous Cell Carcinoma
Neoadjuvant cemiplimab elicited promising pathologic complete responses in patients with cutaneous squamous cell carcinoma.
Pembrolizumab Potentially Most Effective Before Surgery in High-Risk Melanoma
The rate of event-free survival associated with pembrolizumab was significantly higher among patients with high-risk melanoma about to undergo surgery than among those who received immunotherapy following surgery.
Trastuzumab Deruxtecan Preserves Quality of Life in Patients With HR+, HER2-Low, Metastatic Breast Cancer
A quality-of-life analysis of the pivotal Destiny-Breast04 trial showed that trastuzumab deruxtecan outperformed physician’s choice of treatment in delaying definitive deterioration.
Cytokine Release Syndrome and Neurotoxicity Emerge as Primary AEs of Interest With Solid Tumor T-Cell Receptor Therapy
In the phase 1 SURPASS trial, 72% of patients with solid tumors developed any-grade cytokine release syndrome following an infusion of ADP-A2M4CD8. The median time to resolution was 5 days.
Sherry Adkins Talks Primary Care Provider Communication Following CAR T-cell Therapy
Sherry Adkins, MSN, ANP-C, discusses some key considerations in ensuring quality patient care after they have completed CAR T-cell therapy at a specialized center.
Adkins Discusses Benefit of Second-line CAR T-Cell Therapy in Large B-Cell Lymphoma
Sherry Adkins, MSN, ANP-C, discusses the significance of incorporating CAR T-cell therapy regimens, such as lisocabtagene autoleucel, into earlier lines of treatment for patients with relapsed/refractory large B-cell lymphoma.
Oncology APPs, Research Nurses Are Uniquely Poised to Tackle irAE Management in Follicular Lymphoma
Because immune-related adverse events can be hard to diagnose, patient education and clear avenues of communication with an oncology care team are critical, according to investigators at the 2022 Pan Pacific Lymphoma Conference.
Improving Onco-Fertility Conversations With Adolescents and Young Adult Patients With Cancer
In this episode of The Vitals, Donna Herrera Bell, MSN, APRN, FNP-C, highlights how nurses can eliminate barriers to fertility discussions among adolescent and young adult patients with cancer.
Revolutionizing Patient-Reported Outcomes in Oncology Care
Patient-reported outcome collections continue to yield more effective and personalized treatments for patients with cancer.
How To Approach Fertility Conversations With AYA Patients as an Oncology Nurse
Conversations surrounding fertility preservation may differ between young men and women with cancer, according to Donna Herrera Bell, MSN, APRN, FNP-C.
Sotigalimab/Pembrolizumab Jumpstarts Immune Activity, Ignites Clinical Responses in Metastatic Melanoma
The CD40 agonist sotigalimab in combination with pembrolizumab yielded promising outcomes in patients with unresectable stage III or IV metastatic melanoma.
Olanzapine Significantly Reduces CINV in Patients Receiving MEC
Reimagining Frailty Screenings in Head and Neck Cancer
Screening for Pain and Depression is Not Enough in Cancer Care
Niraparib-Based Triplet Therapy Offers OS Advantage in BRCA1/2+ mCRPC
2 Clarke Drive Cranbury, NJ 08512